HBK Sorce Advisory LLC Acquires 30,931 Shares of Pfizer Inc. (NYSE:PFE)

HBK Sorce Advisory LLC lifted its position in Pfizer Inc. (NYSE:PFE - Free Report) by 27.3% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 144,064 shares of the biopharmaceutical company's stock after buying an additional 30,931 shares during the quarter. HBK Sorce Advisory LLC's holdings in Pfizer were worth $3,651,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of PFE. Rialto Wealth Management LLC bought a new position in Pfizer during the fourth quarter worth $26,000. Clarity Asset Management Inc. bought a new position in shares of Pfizer during the 4th quarter worth about $27,000. Gould Capital LLC raised its position in shares of Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after buying an additional 493 shares during the last quarter. Kohmann Bosshard Financial Services LLC bought a new stake in shares of Pfizer in the fourth quarter valued at about $28,000. Finally, Bernard Wealth Management Corp. acquired a new stake in Pfizer during the fourth quarter worth about $30,000. 68.36% of the stock is owned by institutional investors.

Analysts Set New Price Targets

PFE has been the subject of several recent research reports. Citigroup reaffirmed a "neutral" rating on shares of Pfizer in a report on Thursday, March 27th. The Goldman Sachs Group reaffirmed a "neutral" rating and issued a $25.00 target price (down from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. UBS Group lifted their price target on shares of Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a research note on Wednesday, April 30th. Guggenheim restated a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. Finally, Hsbc Global Res upgraded shares of Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, four have assigned a buy rating and three have issued a strong buy rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $29.17.

Pfizer Price Performance

Shares of NYSE:PFE traded down $0.02 during trading on Wednesday, reaching $24.29. The stock had a trading volume of 25,591,071 shares, compared to its average volume of 41,231,244. The stock has a market capitalization of $138.10 billion, a PE ratio of 17.60, a P/E/G ratio of 0.87 and a beta of 0.57. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.26 and a quick ratio of 0.96. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $31.54. The business's 50-day moving average price is $23.33 and its 200 day moving average price is $24.87.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping analysts' consensus estimates of $0.67 by $0.25. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The company had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. During the same quarter in the previous year, the firm earned $0.82 earnings per share. The business's revenue was down 7.8% on a year-over-year basis. As a group, equities analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 7.08%. Pfizer's dividend payout ratio (DPR) is presently 124.64%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.